信达生物(01801)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01801 信达生物

交易中 01-12 14:20:38

89.600

+0.300

+0.34%

最高90.450	最低88.000	成交量771.37万
今开89.200	昨收89.300	日振幅2.74%
总市值1,555亿	流通市值1,555亿	总股本17.35亿
成交额6.88亿	换手率0.44%	流通股本17.35亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01801","market":"HK","secType":"STK","nameCN":"信达生物","latestPrice":89.6,"timestamp":1768198832961,"preClose":89.3,"halted":0,"volume":7713734,"delay":0,"floatShares":1735000000,"shares":1735000000,"eps":-0.06500707210774075,"marketStatus":"交易中","change":0.3,"latestTime":"01-12 14:20:38","open":89.2,"high":90.45,"low":88,"amount":687752200,"amplitude":0.027436,"askPrice":89.7,"askSize":34500,"bidPrice":89.6,"bidSize":13000,"shortable":3,"etf":0,"ttmEps":0.7542725431929419,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1768205400000},"marketStatusCode":2,"adr":0,"listingDate":1540915200000,"exchange":"SEHK","adjPreClose":89.3,"openAndCloseTimeList":[[1768181400000,1768190400000],[1768194000000,1768204800000]],"volumeRatio":0.727167,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"INB.HK","impliedVol":0.4936,"impliedVolPercentile":0.1707},"requestUrl":"/m/hq/s/01801","defaultTab":"news","newsList":[{"id":"2602960582","title":"罗氏从5.7亿美元从宜联生物引进B7H3 ADC，加码SCLC布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2602960582","media":"Minhua笔记","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602960582?lang=zh_cn&edition=full","pubTime":"2026-01-10 16:41","pubTimestamp":1768034502,"startTime":"0","endTime":"0","summary":"1月8日，罗氏宣布与宜联生物达成一项最高达5.7亿美元的授权许可协议，获得后者靶向B7H3的ADC tambotatug pelitecan中国以外地区的全球独家权益。双方于2024年初首次合作，达成一项价值近10亿美元的协议，共同开发宜联生物的ADC药物YL211，该药物靶向c-Met，用于治疗实体瘤。据宜联生物称，初步数据显示，该药物在SCLC二线治疗中展现出令人鼓舞的客观缓解率和生存获益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260110164641a4b35e86&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260110164641a4b35e86&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2488822045.USD","LU2097828714.EUR","LU2242644610.SGD","LU2097828557.USD","LU2097828805.USD","BK1161","LU2097828474.EUR","LU0455707207.USD","LU1969619763.USD","LU2097828631.EUR","LU2328871848.SGD","HK0000165453.HKD","MRK","BK1583","LU0502904849.HKD","BK1589","01801"],"gpt_icon":0},{"id":"2602585844","title":"小核酸药物行业跟踪点评：技术迭代驱动 慢病市场打开成长空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2602585844","media":"光大证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602585844?lang=zh_cn&edition=full","pubTime":"2026-01-10 00:00","pubTimestamp":1767974400,"startTime":"0","endTime":"0","summary":"这意味着小核酸药物的战场已从肝脏疾病全面扩展至代谢、肺部、肌肉萎缩等肝脏外领域。从“跟随”到“并跑”，中国小核酸药物行业BD 出海创历史新高：中国小核酸药物行业在2025 年迎来了质的飞跃。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260110112653a4b29978&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260110112653a4b29978&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","01877","BK1161","01801","BK1515"],"gpt_icon":0},{"id":"2602786673","title":"信达生物01月09日获主力加仓5080.7万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2602786673","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602786673?lang=zh_cn&edition=full","pubTime":"2026-01-09 16:15","pubTimestamp":1767946533,"startTime":"0","endTime":"0","summary":"01月09日, 信达生物股价涨0.34%，报收89.30元，成交金额9.2亿元，换手率0.60%，振幅2.75%，量比0.74。信达生物今日主力资金净流入5080.7万元，连续5日净流入，上一交易日主力净流入1536.9万元。近一年数据显示，该股主力连续5日净流入后，次日上涨概率为60.00%，平均涨幅为9.34%。该股近5个交易日上涨13.77%，主力资金累计净流入2.1亿元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流出1.7亿元，其中净流出天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260109161816a4af6cca&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260109161816a4af6cca&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2097828631.EUR","BK1583","LU0455707207.USD","HK0000165453.HKD","LU2097828557.USD","LU0502904849.HKD","BK1161","01801","LU2097828805.USD","LU2242644610.SGD","LU2328871848.SGD","LU1969619763.USD","LU2488822045.USD","LU2097828714.EUR","BK1589","LU2097828474.EUR"],"gpt_icon":0},{"id":"2602884312","title":"【券商聚焦】华泰证券：开年以来的流动性修复有望提振创新药板块β","url":"https://stock-news.laohu8.com/highlight/detail?id=2602884312","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602884312?lang=zh_cn&edition=full","pubTime":"2026-01-09 08:58","pubTimestamp":1767920334,"startTime":"0","endTime":"0","summary":"金吾财讯 | 华泰证券表示，自9月港股创新药年内新高以来，港股创新药指数截止到年底回调24%，而同期美股生物科技指数XBI涨幅29%，NBI指数涨幅18%。XBI自4月底部反弹超过100%，大型MNC普遍自底部反弹30~50%，礼来市值首次突破万亿美金。步入新的一年，港股创新药迎来开门红。随着流动性修复及对外BD持续，以及JPM峰会、年报周期的BD旺季和数据披露高峰的到来，该机构认为开年以来的流动性修复有望提振创新药板块β，上涨趋势有望持续。","market":"sg","thumbnail":"https://static.szfiu.com/news/20241108/MjAwMmJhMzhlMzU2ODgyNzA0NzY4MTcyNA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MjAwMmJhMzhlMzU2ODgyNzA0NzY4MTcyNA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1972900","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926","BK1141","IE00B5MMRT66.SGD","01877","LU0417516571.SGD","LU1226287792.SGD","LU0588546209.SGD","LU1979443071.USD","LU1934453819.USD","06160","02616","02142","09688","LU2097828805.USD","LU3063872942.SGD","LU1960683339.HKD","LU0516423174.USD","06185","LU0067412154.USD","LU0315179316.USD","LU0502904849.HKD","LU1064131003.USD","02269","LU1807302812.USD","LU0516422952.EUR","159992","01177","BK1589","01093","06978","IE0008369823.USD","LU0561508036.HKD","BK0183","BK0012","LU2476274720.SGD","LU0307460666.USD","LU1328277881.USD","LU0501845795.SGD","LU1993786604.SGD","LU2097828474.EUR","LU0039217434.USD","LU0516422440.USD","BK1500","09995","LU1152091168.USD","LU2148510915.USD","LU1242518857.USD","01801","LU0043850808.USD","601688"],"gpt_icon":0},{"id":"1101154304","title":"信达生物合作伙伴奥霖生物公布IBI324头对头研究积极顶线数据：治疗糖尿病黄斑水肿及湿性年龄相关性黄斑变性疗效优于法瑞西单抗","url":"https://stock-news.laohu8.com/highlight/detail?id=1101154304","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1101154304?lang=zh_cn&edition=full","pubTime":"2026-01-09 08:00","pubTimestamp":1767916835,"startTime":"0","endTime":"0","summary":"信达生物制药的战略合作伙伴奥霖生物近日宣布，其创新药物IBI324在针对糖尿病黄斑水肿与湿性年龄相关性黄斑变性的随机头对头临床研究中取得突破性进展。研究顶线数据显示，与罗氏旗下法瑞西单抗（商品名：Vabysmo®）相比，IBI324展现出更优的治疗效果。\n该研究采用随机对照设计，直接对比两种药物在相同患者群体中的疗效与安全性。结果表明，IBI324在主要终点指标上显著优于对照组，为眼底疾病治疗领域提供了新的潜在解决方案。此次积极数据不仅验证了IBI324的临床价值，也为后续全球临床开发计划奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2097828714.EUR","HK0000165453.HKD","LU2097828805.USD","BK1589","BK1161","LU2097828557.USD","LU2097828631.EUR","LU2242644610.SGD","LU0502904849.HKD","01801","LU2328871848.SGD","LU2488822045.USD","LU2097828474.EUR","LU1969619763.USD","BK1583","LU0455707207.USD"],"gpt_icon":0},{"id":"2602348564","title":"信达生物合作伙伴Ollin宣布IBI324头对头法瑞西单抗临床Ib期研究积极顶线数据，显示更优疗效","url":"https://stock-news.laohu8.com/highlight/detail?id=2602348564","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602348564?lang=zh_cn&edition=full","pubTime":"2026-01-09 08:00","pubTimestamp":1767916800,"startTime":"0","endTime":"0","summary":"OLN324相较法瑞西单抗在视网膜积液消退的速度和幅度上展现出的差异极具说服力，并具有明确的临床意义。\" Ollin Biosciences联合创始人兼首席执行官Jason Ehrlich医学博士表示：\"OLN324是首个也是目前唯一一个在随机、头对头临床研究中显示出解剖学疗效优于市场领先药物法瑞西单抗的治疗方案。在安全性方面，OLN324显示出良好的安全性特征。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4859017_ZH59017_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1583","LU1969619763.USD","LU2097828714.EUR","01801","LU0502904849.HKD","HK0000165453.HKD","LU2097828474.EUR","LU2328871848.SGD","LU0455707207.USD","LU2488822045.USD","BK4139","LU2097828805.USD","LU2242644610.SGD","IVBIY","BK1161","LU2097828557.USD","BK1589","LU2097828631.EUR"],"gpt_icon":0},{"id":"2602669378","title":"人民日报关注｜苏州信达生物制药免疫学副总裁熊慧中：原始创新之路虽难必行","url":"https://stock-news.laohu8.com/highlight/detail?id=2602669378","media":"金台资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602669378?lang=zh_cn&edition=full","pubTime":"2026-01-09 07:29","pubTimestamp":1767914950,"startTime":"0","endTime":"0","summary":"江苏苏州信达生物制药免疫学副总裁熊慧中原始创新之路虽难必行《人民日报》信达生物制药研发大楼里，有300多名研发人员在进行创新药物研发。今年1月1日，随着该药纳入国家医保目录，价格降幅超60%。1月9日，《人民日报》第19版版面。江苏将生物医药作为战略性新兴产业重点培育，为企业持续创新提供有力支持。此外，苏州搭建的产学研协同平台，推动信达生物与本地医疗机构建立临床试验合作，加速创新成果向临床应用转化。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260109073227a7049abe&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260109073227a7049abe&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2097828631.EUR","LU1969619763.USD","LU0455707207.USD","LU2097828474.EUR","HK0000165453.HKD","BK1583","01801","LU2488822045.USD","LU2097828714.EUR","LU2097828805.USD","LU2242644610.SGD","LU0502904849.HKD","BK1161","LU2328871848.SGD","BK1589","BK1191","LU2097828557.USD","BK1574","01477"],"gpt_icon":0},{"id":"2601655083","title":"小摩增持信达生物(01801)约317.3万股 每股作价约78.45港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2601655083","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601655083?lang=zh_cn&edition=full","pubTime":"2026-01-08 18:57","pubTimestamp":1767869847,"startTime":"0","endTime":"0","summary":"1月2日，小摩增持信达生物(01801)317.3036万股，每股作价78.4477港元，总金额约为2.49亿港元。","market":"fut","thumbnail":"https://img.zhitongcaijing.com/image/20260108/20260108185819_24021.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260108/20260108185819_24021.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1390489.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"小摩增持信达生物(01801)约317.3万股 每股作价约78.45港元","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["HK0000165453.HKD","LU0689472784.USD","IE0034235303.USD","LU2023250504.SGD","LU1366192091.USD","BK1583","LU1280957306.USD","LU1670628061.USD","LU2237443622.USD","BK4585","LU1974910355.USD","LU0323591593.USD","LU2054465674.USD","LU0203347892.USD","LU2097828631.EUR","LU2237443382.USD","IE00BKDWB100.SGD","BK4588","LU0238689110.USD","LU2097828714.EUR","LU2237443895.HKD","BK4550","LU2417539215.USD","LU0868494617.USD","LU0976567544.SGD","LU2357305700.SGD","IE00BYXW3230.USD","LU1162221912.USD","LU2097828805.USD","01801","LU0265550359.USD","LU1032466523.USD","IE00BDRTCR15.USD","LU0640476718.USD","LU0868494708.USD","LU0310799852.SGD","LU1894683348.USD","LU0496365809.HKD","LU2237443978.SGD","LU2097828557.USD","LU0048584097.USD","LU1119994496.HKD","LU2237443549.SGD","LU0215105999.USD","LU0820561909.HKD","IE00B1BXHZ80.USD","LU0256863811.USD","LU2213496289.HKD","LU1116320737.USD","IE00B1XK9C88.USD"],"gpt_icon":0},{"id":"2601780452","title":"信达生物01月07日获主力加仓8233.0万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2601780452","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601780452?lang=zh_cn&edition=full","pubTime":"2026-01-07 16:16","pubTimestamp":1767773764,"startTime":"0","endTime":"0","summary":"01月07日, 信达生物股价涨5.38%，报收89.05元，成交金额17.4亿元，换手率1.16%，振幅6.15%，量比1.47。信达生物今日主力资金净流入8233.0万元，连续3日净流入，上一交易日主力净流入1425.3万元。近一年数据显示，该股主力连续3日净流入后，次日上涨概率为80.00%，平均涨幅为2.65%。该股近5个交易日上涨13.08%，主力资金累计净流入1.2亿元；近20日主力资金累计净流出2.8亿元，其中净流出天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260107162328a6fdd074&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260107162328a6fdd074&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000165453.HKD","LU2097828805.USD","BK1589","LU0502904849.HKD","LU2328871848.SGD","LU1969619763.USD","LU2097828557.USD","LU2488822045.USD","BK1161","01801","LU2097828474.EUR","LU2097828631.EUR","LU0455707207.USD","LU2242644610.SGD","LU2097828714.EUR","BK1583"],"gpt_icon":0},{"id":"2601804526","title":"信达生物与健之佳签署2026年战略合作协议，以创新疗法服务更广阔患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2601804526","media":"证券之星APP","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601804526?lang=zh_cn&edition=full","pubTime":"2026-01-07 14:07","pubTimestamp":1767766036,"startTime":"0","endTime":"0","summary":"1月5日，“信启新程，健赢未来”信达生物与健之佳战略合作对接会圆满举行。信达生物、健之佳集团的代表及核心团队齐聚一堂，共同回顾了2025年携手取得的卓越成就，并正式签署2026年战略合作协议。在全体与会人员的共同见证下，信达生物创始人、董事会主席、首席执行官俞德超博士与健之佳董事长、总裁蓝波先生，分别代表双方郑重签署了2026年战略合作协议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260107141125a4a654c2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260107141125a4a654c2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","LU2097828474.EUR","LU2097828714.EUR","LU0455707207.USD","HK0000165453.HKD","LU2097828805.USD","BK1589","LU2097828557.USD","LU2242644610.SGD","01801","LU2488822045.USD","LU2328871848.SGD","LU1969619763.USD","BK1583","LU0502904849.HKD","LU2097828631.EUR"],"gpt_icon":0},{"id":"2601760808","title":"港股创新药ETF基金涨近3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601760808","media":"云掌财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601760808?lang=zh_cn&edition=full","pubTime":"2026-01-07 13:58","pubTimestamp":1767765495,"startTime":"0","endTime":"0","summary":"盘面上，港股创新药表现活跃，凯莱英飙涨7%，泰格医药、昭衍新药、康方生物涨超5%，和黄医药、翰森制药、恒瑞医药等个股涨超4%。截至10：34，热门ETF——港股创新药ETF基金上涨2.85%，冲击三连涨！数据显示，港股创新药ETF基金近60日“吸金”超1亿；最新基金规模达9.39亿元。港股创新药ETF基金跟踪中证港股通创新药指数，指数编制方式更科学合理，成分股涵盖如百济神州、信达生物和药明生物等领军企业。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260107135820a4a649a2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260107135820a4a649a2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","00013","02315","01801","BK1191","01276","06978","03692","06127","09926","06821","BK1161","02269"],"gpt_icon":0},{"id":"2601868644","title":"中信建投：脑机接口有望打开万亿市场空间 需发掘国家政策支持和具有真实需求“真脑机”","url":"https://stock-news.laohu8.com/highlight/detail?id=2601868644","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601868644?lang=zh_cn&edition=full","pubTime":"2026-01-06 11:27","pubTimestamp":1767670058,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中信建投发布研报称，脑机接口升级为十五五产业战略，多重政策强力支持下，产业落地有望提速，建议重视投资机遇。脑机接口是医疗投资也是科技投资，短期来看主要应用于疾病治疗，长期来看若能实现增强人、并与AI和机器人融合，有望打开万亿市场空间。在投资方向选择方面，非侵入式和侵入式脑机接口无优劣之分，但需发掘国家政策支持和具有真实需求的“真脑机”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106113407a6f87063&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106113407a6f87063&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1046422090.SGD","09926","LU2242644610.SGD","BK1576","BK1583","SHPMY","LU0320764599.SGD","01801","06160","02359","01177","LU0052750758.USD","BK1141","LU2045819591.USD","BK1161","LU0708995583.HKD","03347","02607","06978","LU2125910500.SGD","00013","01099","BK1574","02269"],"gpt_icon":0},{"id":"2601854186","title":"千亿出海潮：中国创新药企驶入全球深水区","url":"https://stock-news.laohu8.com/highlight/detail?id=2601854186","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601854186?lang=zh_cn&edition=full","pubTime":"2026-01-06 07:13","pubTimestamp":1767654792,"startTime":"0","endTime":"0","summary":"中国药企不仅成为全球医药研发体系中不可忽视的力量，也在重新定义自身在国际市场上的角色。从首付款到里程碑款的持续流入，标志着中国创新药的全球开发已实质性推进至临床中后期乃至商业化阶段。这意味着中国药企不再只是技术提供方，而是以平等伙伴身份参与全球价值创造与分配。中国药企在跨境谈判、知识产权布局、国际争议解决等方面经验仍显不足。锻造出海“航母舰队”中国创新药的集体出海，离不开产业集群的支撑。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106071431a6f7878c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106071431a6f7878c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01167","00013","BMS","06160","01541","BK4585","BK4139","CXO","ONC","BK4526","01801","02509"],"gpt_icon":0},{"id":"2601186536","title":"每日卖空追踪 | 信达生物 01月05日卖空量成交154.55万股，卖空比例为8.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601186536","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601186536?lang=zh_cn&edition=full","pubTime":"2026-01-05 16:30","pubTimestamp":1767601824,"startTime":"0","endTime":"0","summary":"信达生物北京时间01月05日，涨6.09%，卖空量成交154.55万股，较上一交易日增加137.22%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105163524a49e2937&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105163524a49e2937&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2097828557.USD","HK0000165453.HKD","LU2097828714.EUR","BK1161","LU2328871848.SGD","LU2488822045.USD","LU2097828474.EUR","BK1583","BK1589","LU1969619763.USD","LU2242644610.SGD","LU0455707207.USD","LU2097828631.EUR","LU0502904849.HKD","01801","LU2097828805.USD"],"gpt_icon":0},{"id":"2601822850","title":"大和：升信达生物同为生物医药首选","url":"https://stock-news.laohu8.com/highlight/detail?id=2601822850","media":"智通财经网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601822850?lang=zh_cn&edition=full","pubTime":"2026-01-05 15:48","pubTimestamp":1767599322,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，大和发布研报称，对于医药个股作建议，首选是信达生物(01801)与恒瑞医药(600276.SH)，信达生物目标价由95港元上调至112港元，恒瑞医药目标价维持80元人民币，并维持对石药集团(01093)的“沽售”评级，目标价维持6.6港元。该行表示，2025年，中国生物医药板块经历了全面上涨;展望2026年，该行建议采取更具选择性、精选个股的策略，聚焦优质标的。针对2026年，大和将：1)列出关键临床数据发布节点，2)梳理影响重大的股价催化剂，3)分析重点领域(PD-(L)1/VEGF、GLP-1、siRNA等)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105155510a6f4f4ae&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105155510a6f4f4ae&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1152091754.HKD","IE00B5MMRT66.SGD","IE00BZ08YR35.GBP","LU0314109678.HKD","BK1161","LU1226287792.SGD","BK1583","LU1226287875.USD","BK1515","SG9999004220.SGD","LU2097828805.USD","LU1960683339.HKD","LU1226288253.USD","LU1008478684.HKD","LU0067412154.USD","LU0315179316.USD","IE00B543WZ88.USD","LU0502904849.HKD","LU2039709279.SGD","LU1807302812.USD","LU2097828631.EUR","BK1589","01093","LU1969619763.USD","IE0008369823.USD","IE0008368742.USD","LU0140636845.USD","IE00BZ08YS42.EUR","LU0072913022.USD","BK1521","LU2242644610.SGD","LU1951186391.HKD","LU1226288170.HKD","LU1226287529.USD","LU2488822045.USD","LU2097828714.EUR","LU1328277881.USD","LU2328871848.SGD","LU0501845795.SGD","LU1993786604.SGD","IE00BZ08YT58.USD","LU0880133367.SGD","LU2097828474.EUR","BK1191","LU1813983027.USD","HK0000165453.HKD","IE00B031HY20.USD","LU1152091168.USD","LU2097828557.USD","01801"],"gpt_icon":0},{"id":"2601437009","title":"信达生物盘中异动 急速上涨3.05%报81.200港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2601437009","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601437009?lang=zh_cn&edition=full","pubTime":"2026-01-05 10:01","pubTimestamp":1767578498,"startTime":"0","endTime":"0","summary":"2026年01月05日早盘10时01分，信达生物股票出现波动，股价急速上涨3.05%。截至发稿，该股报81.200港元/股，成交量310.265万股，换手率0.18%，振幅5.52%。资金方面，该股资金流入1.35412亿港元，流出8060.49万港元。信达生物股票所在的药品行业中，整体跌幅为0.22%。其相关个股中，中国同辐、中智药业、兆科眼科-B涨幅较大，振幅较大的相关个股有宝济药业-B、中智药业、长风药业，振幅分别为11.76%、10.00%、8.54%。该公司主要在中国国内和海外市场开展业务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105100138a6f3c411&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105100138a6f3c411&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2097828805.USD","LU2488822045.USD","BK1161","LU0455707207.USD","LU2328871848.SGD","LU2097828631.EUR","LU2097828474.EUR","LU2097828714.EUR","01801","HK0000165453.HKD","LU2242644610.SGD","LU2097828557.USD","BK1589","LU1969619763.USD","BK1583","LU0502904849.HKD"],"gpt_icon":0},{"id":"2601029158","title":"恒瑞、百济双雄挺进TOP20！翰森、博泰加速冲刺，11家中国药企入榜，药企市值TOP50大洗牌","url":"https://stock-news.laohu8.com/highlight/detail?id=2601029158","media":"E药经理人","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601029158?lang=zh_cn&edition=full","pubTime":"2026-01-04 21:09","pubTimestamp":1767532195,"startTime":"0","endTime":"0","summary":"2025年的全球药企市值TOP50榜单，不再是跨国巨头的独角戏，11家中国药企集体亮剑。从“还差临门一脚”到稳坐TOP20一隅如果将时间拨回到2023年，中国药企在全球市值TOP50中的处境，常被形容为还差“临门一脚”。而到了2025年末，中国药企在全球药企市值的排行已经发生了实质性改变。恒瑞在2025年中登陆港交所后，其在港股市值一度突破5000亿港元。首次冲进全球制药企业市值TOP20的百济，则代表着另一条路径。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260104212120a6f20aa3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260104212120a6f20aa3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1191","BK1589","01801","03692","09926","LU0196878994.USD","06990","06160","BK1583"],"gpt_icon":0},{"id":"2601091780","title":"减肥药中场战事：MNC筑墙，本土玩家圈地","url":"https://stock-news.laohu8.com/highlight/detail?id=2601091780","media":"建国路128号","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601091780?lang=zh_cn&edition=full","pubTime":"2026-01-04 19:10","pubTimestamp":1767525010,"startTime":"0","endTime":"0","summary":"礼来替尔泊肽在医保谈判中大幅降价的传闻，是近期资本市场减肥药板块的一大话题。替尔泊肽此次在中国市场的激进动作，对国产减重药而言，无疑是一次重大考验。这意味着中国本土药企同样具备了产出全球最高级别临床证据的能力。要知道，在中国肥胖总体人群中，最常见的并发症就是脂肪肝，肥胖患者合并脂肪肝的比例高达81.8%，属于肥胖合并脂肪肝的“重灾区”。肥胖超重合并脂肪肝总患病数接近3亿。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260104210333a6f1fe79&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260104210333a6f1fe79&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01801","BK1583","HK0000165453.HKD","LU2097828631.EUR","LU2328871848.SGD","LU0455707207.USD","LU2488822045.USD","LU2097828557.USD","LU2242644610.SGD","LU2097828714.EUR","LU0502904849.HKD","BK1161","LU2097828805.USD","LU2097828474.EUR","BK1589","LU1969619763.USD"],"gpt_icon":0},{"id":"2600655340","title":"美股偏软道指跌0.63% 恒指继续反复靠稳","url":"https://stock-news.laohu8.com/highlight/detail?id=2600655340","media":"真灼财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600655340?lang=zh_cn&edition=full","pubTime":"2026-01-02 20:55","pubTimestamp":1767358556,"startTime":"0","endTime":"0","summary":"美股三大指数全线下跌，当中道指跌0.63%，标普500指数及纳指则均跌超过0.7%，反映中概股表现之金龙指数亦下跌超过1%。中港股市方面，沪深两市个别发展，上综指微升3点，收报3,968点，深成指则跌0.58%，收报13,525点，两市成交超过2万亿元人民币。总结2025年表现，恒指累升5,570或27%，表现为近8年最佳，科指升幅亦逾23%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260102211021a494c066&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260102211021a494c066&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SDOW","TQQQ","BK4593","BK4585","SPY","BK4534","BK4588","01801","DOG","BK4550","UDOW","02382","MYMmain","DDM","QQQ","BK4614","09999","DJX","DXD","NTES","HSTECH","BK4561","BK4581","HSI"],"gpt_icon":1},{"id":"2600550960","title":"信达生物盘中异动 早盘快速拉升3.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2600550960","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600550960?lang=zh_cn&edition=full","pubTime":"2026-01-02 11:18","pubTimestamp":1767323909,"startTime":"0","endTime":"0","summary":"2026年01月02日早盘11时18分，信达生物股票出现波动，股价快速拉升3.02%。截至发稿，该股报78.550港元/股，成交量158.39万股，换手率0.09%，振幅2.36%。资金方面，该股资金流入5124.38万港元，流出5367.32万港元。机构评级方面，在所有21家参与评级的机构中，90%的券商给予买入建议，10%的券商给予持有建议，无券商给予卖出建议。信达生物股票所在的药品行业中，整体涨幅为0.89%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260102111829a6ea7b38&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260102111829a6ea7b38&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2328871848.SGD","LU2097828557.USD","BK1161","LU2242644610.SGD","LU0455707207.USD","LU0502904849.HKD","LU2097828474.EUR","LU2097828631.EUR","LU2097828805.USD","LU2097828714.EUR","LU2488822045.USD","LU1969619763.USD","01801","BK1583","BK1589","HK0000165453.HKD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.innoventbio.com","stockEarnings":[{"period":"1week","weight":0.1332},{"period":"1month","weight":0.0695},{"period":"3month","weight":-0.0495},{"period":"6month","weight":0.1086},{"period":"1year","weight":1.6979},{"period":"ytd","weight":0.1711}],"compareEarnings":[{"period":"1week","weight":-0.0041},{"period":"1month","weight":0.0271},{"period":"3month","weight":-0.0022},{"period":"6month","weight":0.0867},{"period":"1year","weight":0.3633},{"period":"ytd","weight":0.0235}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"信达生物制药是一家主要从事研发、生产及销售治疗肿瘤、心血管及代谢（CVM）、自身免疫及眼科等重大疾病创新药物的投资控股公司。药物形式包括单克隆抗体、多特异性抗体、免疫细胞因子、抗体偶联药物（ADC）、细胞治疗及小分子药物等。该公司的主要产品包括达伯舒（信迪利单抗注射液）、达攸同（贝伐珠单抗注射液）、苏立信（阿达木单抗注射液）、达伯华（利妥昔单抗注射液）、达伯坦（佩米替尼片）等。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.027634},{"month":2,"riseRate":0.714286,"avgChangeRate":0.11927},{"month":3,"riseRate":0.285714,"avgChangeRate":-0.021767},{"month":4,"riseRate":0.714286,"avgChangeRate":0.040816},{"month":5,"riseRate":0.428571,"avgChangeRate":0.027398},{"month":6,"riseRate":0.714286,"avgChangeRate":0.139165},{"month":7,"riseRate":0.428571,"avgChangeRate":0.010056},{"month":8,"riseRate":0.714286,"avgChangeRate":0.000214},{"month":9,"riseRate":0.571429,"avgChangeRate":0.032182},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.02286},{"month":11,"riseRate":0.625,"avgChangeRate":0.079172},{"month":12,"riseRate":0.375,"avgChangeRate":0.024026}],"exchange":"SEHK","name":"信达生物","nameEN":"INNOVENT BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"信达生物(01801)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供信达生物(01801)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"信达生物,01801,信达生物股票,信达生物股票老虎,信达生物股票老虎国际,信达生物行情,信达生物股票行情,信达生物股价,信达生物股市,信达生物股票价格,信达生物股票交易,信达生物股票购买,信达生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"信达生物(01801)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供信达生物(01801)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}